Silence Therapeutics plc (NASDAQ:SLN) Short Interest Down 26.1% in July

Silence Therapeutics plc (NASDAQ:SLN) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 560,700 shares, a drop of 26.1% from the June 30th total of 759,200 shares. Based on an average daily volume of 157,700 shares, the short-interest ratio is currently 3.6 days.

Silence Therapeutics Price Performance

Shares of SLN stock traded down $0.03 on Friday, hitting $20.99. The stock had a trading volume of 355,353 shares, compared to its average volume of 214,903. The company’s 50 day moving average price is $20.35 and its 200-day moving average price is $21.40. Silence Therapeutics has a 1 year low of $4.88 and a 1 year high of $27.72. The firm has a market capitalization of $628.23 million, a P/E ratio of -18.09 and a beta of 1.30.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.18. The firm had revenue of $15.73 million during the quarter, compared to analysts’ expectations of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. On average, equities analysts forecast that Silence Therapeutics will post -1.52 EPS for the current year.

Hedge Funds Weigh In On Silence Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new stake in shares of Silence Therapeutics during the 4th quarter worth $110,000. Vivo Capital LLC acquired a new position in shares of Silence Therapeutics during the 4th quarter worth about $8,862,000. Parkman Healthcare Partners LLC increased its holdings in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after acquiring an additional 40,063 shares during the last quarter. Redmile Group LLC acquired a new stake in shares of Silence Therapeutics during the 1st quarter worth about $43,798,000. Finally, Janus Henderson Group PLC purchased a new stake in Silence Therapeutics during the first quarter worth approximately $13,575,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently weighed in on SLN shares. HC Wainwright restated a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a report on Thursday, June 27th. Chardan Capital upped their target price on Silence Therapeutics from $42.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 28th. Finally, Morgan Stanley lifted their price target on Silence Therapeutics from $45.00 to $49.00 and gave the stock an “overweight” rating in a report on Friday, June 28th.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.